Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
141 results about "Quetiapine" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
This medication is used to treat certain mental/mood conditions (such as schizophrenia, bipolar disorder, sudden episodes of mania or depression associated with bipolar disorder).
Quetiapine formulations
The invention provides novel dosage forms of quetiapine and its salts, particularly quetiapine hemifumarate including wax dosage forms, press-coat dosage forms, and sprinkle dosage forms, and other novel dosage forms. The invention also provides sustained release and pulsed release dosage forms of quetiapine and its salts. Methods of making novel quetiapine dosage forms are given. Methods of treating schizophenia and other neuropsychiatric disorders by administering an effective amount of the dosage forms disclosed herein, either alone or in combination with one or more other medicaments, are also provided by the invention
Owner:ACTAVIS GRP PTC EHF
Quetiapine formulations
The invention provides novel dosage forms of quetiapine and its salts, particularly quetiapine hemifumarate including wax dosage forms, press-coat dosage forms, and sprinkle dosage forms, and other novel dosage forms. The invention also provides sustained release and pulsed release dosage forms of quetiapine and its salts. Methods of making novel quetiapine dosage forms are given. Methods of treating schizophenia and other neuropsychiatric disorders by administering an effective amount of the dosage forms disclosed herein, either alone or in combination with one or more other medicaments, are also provided by the invention
Owner:BOEHM GARTH +1
Processes for preparing quetiapine and salts thereof
The present invention provides herein a two-step process for preparing pharmaceutically pure quetiapine and salts thereof by obtaining the starting material 11-chloro-dibenzo-thiazepine followed by reacting the 11-chloro-dibenzo-thiazepine with 1-(2-hydroxyethoxy)ethylpiperazine, or its salt, in the presence of an inorganic or organic base in an organic solvent or in a two-phase solvent system. The present invention provides also a novel, one-pot reaction process for preparing pharmaceutically pure quetiapine and salts thereof. The two processes provided herein can be easily, conveniently and inexpensively scaled-up.
Owner:CHEMAGIS
Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
The use of phosphodiesterase 5 (PDE5) inhibitors for treatment of schizophrenia is described. Suitable PDE5 inhibitors for use for treatment of schizophrenia include sildenafil, vardenafil, tadalafil, E-8010, zaprinast, and E-4021. In one embodiment, for example, a method is described for treating schizophrenia in a patient which comprises treating the patient with an effective amount of a PDE5 inhibitor, or a pharmaceutically acceptable salt, solvate, or composition thereof. The PDE5 inhibitor may be administered orally. The PDE5 inhibitor may also be administered together with one or more conventional antipsychotic medications such as risperidone, olanzapine, quetiapine, ziprasidone, aripiprazole, clozapine, haloperidol, and fluphenazine.
Owner:SHARY CIRCLE
Haptens of quetiapine
The invention relates to compounds of Formula I, wherein R1, R2, and R3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from quetiapine. The invention also relates to conjugates of a quetiapine hapten and a protein.
Owner:JANSSEN PHARMA NV
Antibodies to Risperidone Haptens and Use Thereof
Disclosed is an antibody which binds to risperidone, which can be used to detect risperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of risperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.
Owner:JANSSEN PHARMA NV
Antibodies to Aripiprazole Haptens and Use Thereof
ActiveUS20140057299A1Bioreactor/fermenter combinationsBiological substance pretreatmentsQuetiapineHapten
Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.
Owner:JANSSEN PHARMA NV
Antibodies to Quetiapine Haptens and Use Thereof
Disclosed is an antibody which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.
Owner:JANSSEN PHARMA NV
Antibodies to Olanzapine and Use Thereof
Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.
Owner:JANSSEN PHARMA NV
Antibodies to Paliperidone and Use Thereof
Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone / paliperidone in a single lateral flow assay device.
Owner:JANSSEN PHARMA NV
Antibodies to Paliperidone Haptens and Use Thereof
Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, risperidone and paliperidone in a single lateral flow assay device.
Owner:JANSSEN PHARMA NV
Antibodies to paliperidone and use thereof
Disclosed is an antibody which binds to paliperidone, which can be used to detect paliperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of paliperidone, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone / paliperidone in a single lateral flow assay device.
Owner:JANSSEN PHARMA NV
Kit for detecting anti-psychosis drugs in serum and plasma by liquid chromatography tandem mass spectrometry method and application thereof
InactiveCN109085263AReduce matrix effectThe test result is accurateComponent separationPsychosis drug9-Hydroxyrisperidone
The invention provides a kit for detecting anti-psychosis drugs in a serum and plasma by a liquid chromatography tandem mass spectrometry method. The kit comprises drug standards: amsulpiride, aripiprazole, dehydroaripiprazole, chlorpromazine, clozapine, n-desmethylclozapine, risperidone, 9-hydroxyrisperidone, quetiapine, olanzapine, ziprasidone; drug internal standard compounds: amplepiride-d5, aripiprazole-d8, chlorpromazine-d3, clozapine-d8, risperidone-d4, 9-hydroxyrisperidone-d4, quetiapine-d8, olanzapine-d8, ziprasidone-d8; drug extraction compounds: methanol solution 60% (volume ratio),acetonitrile solution 20%, isopropanol solution 10%, purified water 10%; negative plasma; and a diluent: 50% aqueous methanol solution. The kit can be used to simultaneously detect anti-psychosis drugs and active metabolites thereof, the detection time is short and the flux is large.
Owner:HANGZHOU BAICHEN MEDICAL INSTR CO LTD +1
Quetiapine analogs and methods of use thereof
InactiveUS20060094705A1Shorten time to sleepIncrease the lengthOrganic active ingredientsBiocideQuetiapineChemistry
Owner:HYPNION INC
Antibodies to risperidone and use thereof
Disclosed is an antibody which binds to risperidone, which can be used to detect risperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of risperidone, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone in a single lateral flow assay device.
Owner:JANSSEN PHARMA NV
Antibodies to aripiprazole haptens and use thereof
Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.
Owner:JANSSEN PHARMA NV
Antibodies to risperidone haptens and use thereof
Disclosed is an antibody which binds to risperidone, which can be used to detect risperidone in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of risperidone, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.
Owner:JANSSEN PHARMA NV
Antibodies to aripiprazole and use thereof
Disclosed is an antibody which binds to aripiprazole, which can be used to detect aripiprazole in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of aripiprazole, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.
Owner:JANSSEN PHARMA NV
Antibodies to quetiapine and use thereof
Disclosed is an antibody which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, quetiapine, olanzapine, and risperidone in a single lateral flow assay device.
Owner:JANSSEN PHARMA NV
Method for synchronously detecting seventeen antipsychotics in blood sample
InactiveCN109668979ARealize detectionAchieving Simultaneous DetectionComponent separation9-HydroxyrisperidoneSolvent
The invention discloses a method for synchronously detecting seventeen antipsychotics in a blood sample. The method comprises the steps that the sample is extracted with a mixed solution of methanol and acetonitrile to obtain supernate, and after a solvent is removed from the supernate, the supernate is dissolved in a methanol aqueous solution and filtered to obtain a specimen; a high performanceliquid chromatography tandem mass spectrometry method is adopted to detect the specimen; the sample is serum or plasma, and the antipsychotics are amisulpride, aripiprazole, dehydro aripiprazole, chlorpromazine, clozapine, desmethylclozapine, fluphenazine, haloperidol, olanzapine, paliperidone, perphenazine, quetiapine, risperidone, 9-hydroxyrisperidone, sulpiride, ziprasidone and thioridazine; inthe high performance liquid chromatography, a mobile phase A is an aqueous solution of formic acid, and a mobile phase B is a methanol solution of the formic acid; and the mass spectrometry adopts amulti-ion reaction monitoring mode of positive ion electrospray ionization.
Owner:JINAN YING SHENG BIOTECH
Haptens of quetiapine
The invention relates to compounds of Formula I, wherein R1, R2, and R3 are defined in the specification, useful for the synthesis of novel conjugates and immunogens derived from quetiapine. The invention also relates to conjugates of a quetiapine hapten and a protein.
Owner:JANSSEN PHARMA NV
Antibodies to quetiapine haptens and use thereof
Disclosed is an antibody which binds to quetiapine, which can be used to detect quetiapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of quetiapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.
Owner:JANSSEN PHARMA NV
Quetiapine sustained release tablets and method of preparing the same
ActiveCN101347413AGood slow releaseSimple processOrganic active ingredientsNervous disorderSustained Release TabletControl release
The invention belongs to the field of pharmaceutical preparations, more specifically relates to a seroquel sustained release tablet and a preparation method thereof. The sustained release tablet of the invention comprises 5%-50% of sustained release framework material with pH-dependent solubility according to weight percentage, and preferably comprises 15%-35% of the sustained release framework material with the pH-dependent solubility. The seroquel sustained release tablet prepared by the invention runs in the gastrointestinal tract by imitating sustained release and controlled release agents, the in vitro release rate thereof is determined, which proves that the sustained seroquel release tablet can continuously release for 6-24 hours. The seroquel sustained release tablet of the invention reduces dosage of sustained release material based on good sustained release performance and facilitates the administration of patients. The seroquel sustained release tablet of the invention has simple technology and is good for large-scale industrialized production at the same time.
Owner:SHANDONG BESTCOMM PHARMA CO LTD
Antibodies to olanzapine and use thereof
Disclosed is an antibody which binds to olanzapine, which can be used to detect olanzapine in a sample such as in a competitive immunoassay method. The antibody can be used in a lateral flow assay device for point-of-care detection of olanzapine, including multiplex detection of aripiprazole, olanzapine, quetiapine, and risperidone in a single lateral flow assay device.
Owner:JANSSEN PHARMA NV
Fatty Acid Conjugates of Quetiapine, Process for Making and Using the Same
InactiveUS20110223207A1Improve bioavailabilityReduced interindividual variabilityBiocideOrganic active ingredientsDrugQuetiapine
The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating fatty acids to quetiapine. Pharmaceutical compositions and methods of synthesizing conjugates of the present technology are also provided. Methods of treating patients with the compositions of the present technology are also provided.
Owner:KEMPHARM INC
Procedure for preparing a pharmaceutically active compound
The invention relates to a procedure for preparing quetiapine by reaction between a compound of formula (II) and a compound of formula (III), in which X means a leaving group and P a protective group of alcohols resistant to alkaline conditions, in the presence of a base, followed by a step of deprotection and, optionally, obtaining a pharmaceutically acceptable salt thereof. Said procedure permits the obtaining of quetiapine with a high degree of purity under soft temperature conditions, with short reaction times and avoiding the use of toxic solvents. (Graphic)
Owner:INKE SA (ES)
Extended release dosage forms of quetiapine
Owner:RANBAXY LAB LTD
Method for simultaneously detecting seven sleep chemical medicines
The invention discloses a supplemental detection method of seven chemical medicines including carbamazepine, chlorpromazine hydrochloride, olanzapine, doxepin hydrochloride, quetiapine fumarate, oxcarbazepine and sulpiride which are illegally added into health-care food or Chinese patent medicine for improving sleep. After a sample is subjected to ultrasonic extraction with methyl alcohol, chromatogram column separation is conducted, a mobile phase is eluted, and DAN detector is used for detection. By means of a built detection method, methodological verification is conducted, and parameters of results are shown in the description. It is verified that the method is quick, high in specificity and suitable for detection of chemical medicine added to the health-care food or Chinese patent medicine for improving sleep.
Owner:SHANXI PROVINCE FOOD & DRUG INSPECTION INST
Amino Acid Conjugates of Quetiapine, Process for Making and Using the Same
The presently described technology provides a novel class of prodrugs of quetiapine that can be synthesized by chemically conjugating amino acids to quetiapine. The present technology also provides methods of treating patients, pharmaceutical compositions and methods of synthesizing conjugates of the present technology.
Owner:KEMPHARM INC
Quetiapine fumarate tablet and preparation method thereof
InactiveCN101940561APromote dissolutionSolve the problem of poor dissolutionOrganic active ingredientsNervous disorderQuetiapineBULK ACTIVE INGREDIENT
The invention provides a quetiapine fumarate tablet which comprises active ingredient quetiapine fumarate or pharmaceutically acceptable salt, and at least one pharmaceutic adjuvant; the quetiapine fumarate tablet also comprises one or more specific acids which can promote a medicine to be rapidly dissolved out; and fumaric acid is preferentially selected. The invention also relates to a preparation method of the quetiapine fumarate tablets. By the invention, the product which can be rapidly dissolved out and has good stability can be acquired, and the quality of the product can be improved.
Owner:ZHEJIANG HUAHAI PHARMA CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com